-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
From retirement to leaving the mountain, as of January 3, 2023, Sun Piaoyang has been in charge of Hengrui for more than 540 days
.
At present, Hengrui Pharmaceutical is still not performing well in the capital market (as of press time, Hengrui Pharmaceutical's market value is only about 245.
8 billion yuan, far from the market value of more than 600 billion yuan at the peak at the end of 2020).
More or less from the pressure of the capital market, Hengrui Pharmaceutical has to accelerate the difficult transformation, in the change of core management, the optimization of sales and R & D personnel structure is also accelerating reform
.
1 Jiang Ningjun joined Hengrui Pharmaceutical
1 Jiang Ningjun joined Hengrui PharmaceuticalAccording to medical representatives, on January 2, Hengrui Pharmaceutical announced the appointment of Jiang Ningjun as the deputy general manager and chief strategy officer of Hengrui Pharmaceutical, responsible for the company's clinical research and business development
.
At this point, the strategic decision-making team of Hengrui Pharmaceutical, composed of Sun Piaoyang, Zhang Lianshan, and Jiang Ningjun, will be fully responsible for Hengrui's strategy and R&D decisions
.
2 Current status of Hengrui's management
2 Current status of Hengrui's managementAfter joining Hengrui Pharmaceutical——
Jiang Ningjun directly reported to Sun Piaoyang, chairman of Hengrui Pharmaceutical; Wang Quanren, another deputy general manager responsible for research and development in the non-oncology field, and Chen Dong, head of business development, both reported
to Jiang Ningjun.
In December 2022, after the departure of Hengrui Pharmaceutical's CMO (oncology) and deputy general manager, Hengrui Pharmaceutical announced that——
Hengrui Pharmaceutical's R&D is still headed by Zhang Lianshan, deputy general manager and global R&D president;
Zhang LianshanShanghai Hengrui R&D center is headed by Dr.
He Feng, deputy general manager of the company;
Shanghai Shengdi Preclinical Development and Translational Medicine is in charge of Dr.
Liao Cheng, Deputy General Manager
.
In addition, Hengrui Pharmaceutical also announced at that time:
Earlier, Shi Wei, Zhu Xiaoyu and Wang Linna were appointed as the deputy general managers of the clinical R&D department, serving as the chief medical officer (CMO) of clinical research of chest, breast tumors and gastrointestinal tumors, respectively, and reported
to Wang Quanren, the deputy general manager of the company in charge of the clinical R&D department.
For these adjustments, Zhang Lianshan, deputy general manager and president of global R&D of Hengrui Pharmaceutical, once said that this is an inevitable process for the company to continue to promote specialization and rejuvenation in the field of R&D management talents, and the recent appointment of a number of young R&D middle and senior managers will help the company to further input "fresh blood"
on the basis of ensuring the continuity and stability of innovation and R&D.
on the basis of ensuring the continuity and stability of innovative R&D.
At the same time, Zhang Lianshan said that with the increasing requirements for specialization in the field of diseases managed by clinical research, the adjustment of the company's clinical management system is imperative
.
.
It can be seen that Hengrui has further optimized the innovative R&D architecture, improved the efficiency of clinical development, and made great determination for the company's new drug research and development!
In order to cope with the pressure of centralized procurement, Hengrui Pharmaceutical promoted sales reform in 2021, and streamlined sales personnel by abolishing the regional hierarchical structure, reducing low-performance provinces, regions and offices, and streamlining sales personnel, optimizing from 17,138 at the beginning of the year to 13,208, and laying off nearly 4,000 people in one year, further reducing sales operating costs
.
In addition, the number of production personnel, financial personnel and administrative personnel of Hengrui Pharmaceutical has been reduced
to varying degrees.
While streamlining and optimizing other positions, Hengrui Pharmaceutical is also expanding its own R&D team
.
Financial report data shows that by the end of 2021, the number of R&D personnel of Hengrui Pharmaceutical reached 5,478, an increase of more than 750 from the end of 2020, and the proportion of R&D personnel to the total number of the company increased from 16.
33% at the end of 2020 to 22.
4
%.
33% at the end of 2020 to 22.
4%.
3 Hengrui management resignation
3 Hengrui management resignationIn 2022, a total of 4 deputy general managers of Hengrui Pharmaceutical will leave
.
It is worth noting that the 4 Hengrui executives who left are not talents trained internally by Hengrui, but "airborne" imported from outside, and their working time in Hengrui is no more than 8 years, and the shortest is less than 4 years
.
On February 25, 2022, Zhang Yuehong, deputy general manager of the company, resigned
.
Zhang Yuehong's whereabouts have not yet been announced
.
Zhang Yuehong, joined Hengrui Pharmaceutical in 2018 and was promoted to deputy general manager in 2020, and has worked in Hengrui Pharmaceutical for nearly 4 years
.
.
On April 12, 2022, Zou Jianjun, deputy general manager of the company, resigned
.
On April 20, Junshi Biologics announced that it has nominated Dr.
Zou Jianjun as an executive director of the company, appointed him as the company's deputy general manager and served as the president
of global research and development.
Zou Jianjun, joined Hengrui Pharmaceutical in 2015 and was promoted to deputy general manager in 2017, serving in Hengrui Pharmaceutical for nearly 7 years
.
.
On October 10, 2022, Tao Weikang, deputy general manager of the company, resigned
.
On October 13, Tao Weikang joined Qilu Pharmaceutical as Group Vice President and General Manager of
Qilu Global Innovative Drug R&D.
Tao Weikang, joined Hengrui Pharmaceutical in 2014 and was promoted to deputy general manager in 2015, and has worked in Hengrui Pharmaceutical for nearly 8 years
.
.
On December 4, 2022, Zhang Xiaojing, CMO of Hengrui Pharmaceutical, resigned
.
On December 7, Antengene announced the appointment of Xiaojing Zhang as the company's chief medical officer
.
Zhang Xiaojing, joined Hengrui Pharmaceutical in 2019 and was promoted to deputy general manager in 2022, and has worked in Hengrui Pharmaceutical for nearly 4 years
.
Attached Jiang Ning Jun Resume:
In August 2022, CStone announced that after leading CStone for 6 years, Dr.
Jiang Ningjun, the founding CEO, decided to retire from CStone and ceased to serve as the Chief Executive Officer, Executive Director, Chairman of the Strategy Committee and authorized representative
of the Company.
Dr.
Jianxin Yang, former Senior Vice President and Chief Medical Officer of CStone, took over as CEO
.
CStone was founded in 2016, and Dr.
Jiang Ningjun joined
CStone as the founding CEO in July of the same year.
Under the leadership of Dr.
Jiang Ningjun, CStone Pharmaceuticals successfully listed on the Hong Kong Stock Exchange in just three years, achieved the listing of 4 FIC/BIC innovative oncology drugs in six years, obtained 9 NDAs, balanced layout of 15 innovative products in the field of oncology, and reached all-round strategic cooperation
with many global leading pharmaceutical companies at home and abroad.
Prior to joining CStone, Dr.
Jiang Ningjun had more than 10 years of experience at Sanofi:
In 2002, he joined Sanofi in the United States as the director of cardiovascular clinical research.
In 2006, he became the vice president of China Clinical Research Center;
In 2008, he became Vice President of China R&D Center, responsible for the company's new drug development and clinical research
in China.
Jiang Ningjun graduated from Nanjing Medical University, received a doctorate degree in immunology from the University of British Columbia, Canada, and completed clinical residency and clinical chemistry postdoctoral training in internal medicine at Washington University School of Medicine in St.
Louis, USA, and holds a medical license
in New Jersey and other states.
References:
References: References:Medical Trends: "Heavy! Jiang Ningjun retired from CStone Pharmaceutical, Yang Jianxin took over as CEO"
Medical Trends: "Heavy! Jiang Ningjun retired from CStone Pharmaceutical, Yang Jianxin took over as CEO"
